Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

ANNX

Annexon Inc

Jul 26 • 04:00PM ET

6.24

Dollar change +0.06
Percentage change 1.05	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO DFAC IWC VFMO ITOT AVSC

Index	RUT	P/E	-	EPS (ttm)	-1.46	Insider Own	20.81%	Shs Outstand	105.41M	Perf Week	10.83%
Market Cap	657.76M	Forward P/E	-	EPS next Y	-1.06	Insider Trans	-0.04%	Shs Float	83.48M	Perf Month	34.19%
Income	-120.74M	PEG	-	EPS next Q	-0.23	Inst Own	74.60%	Short Float	6.99%	Perf Quarter	35.95%
Sales	0.00M	P/S	-	EPS this Y	44.85%	Inst Trans	10.07%	Short Ratio	1.99	Perf Half Y	35.65%
Book/sh	2.90	P/B	2.15	EPS next Y	-8.13%	ROA	-42.15%	Short Interest	5.84M	Perf Year	85.16%
Cash/sh	2.51	P/C	2.48	EPS next 5Y	38.60%	ROE	-50.60%	52W Range	1.57 - 8.40	Perf YTD	37.44%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-29.69%	ROI	-41.50%	52W High	-25.71%	Beta	1.24
Dividend TTM	-	Quick Ratio	20.62	Sales past 5Y	0.00%	Gross Margin	-	52W Low	297.45%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	20.62	EPS Y/Y TTM	40.91%	Oper. Margin	0.00%	RSI (14)	62.87	Volatility	7.46% 8.37%
Employees	71	Debt/Eq	0.12	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	15.67
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	60.82%	Payout	-	Rel Volume	0.40	Prev Close	6.18
Sales Surprise	-	EPS Surprise	38.18%	Sales Q/Q	-	Earnings	May 13 BMO	Avg Volume	2.94M	Price	6.24
SMA20	15.09%	SMA50	19.02%	SMA200	40.71%	Trades		Volume	1,179,864	Change	1.05%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-24	Upgrade	JP Morgan	Neutral → Overweight	$11
Dec-21-23	Upgrade	BofA Securities	Neutral → Buy	$4 → $6
Oct-30-23	Initiated	Wells Fargo	Overweight	$11
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Jul-16-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.02%
Jul-11-24 06:09PM	Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +8.53% +11.15%
Jun-29-24 08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
Jun-28-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks)
Jun-27-24 09:55AM	Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
05:00PM	Loading…
Jun-25-24 05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
Jun-18-24 08:00AM	Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barr Syndrome At 2024 PNS Annual Meeting (GlobeNewswire) -5.41%
Jun-17-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 11:04PM	Annexon Announces Pricing of $125 Million Underwritten Public Offering (GlobeNewswire) +13.36% -13.25%
10:57AM	Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals (Zacks)
09:55AM	Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet (Zacks)
04:45AM	Annexons ANX005 offers improvement in Phase III GBS trial (Clinical Trials Arena)
05:06PM	Loading…
Jun-04-24 05:06PM	Annexon Announces Proposed Public Offering of Common Stock (GlobeNewswire) +30.79%
12:06PM	Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study (Benzinga)
08:46AM	Annexon shares leap as Guillain-Barr drug reduces disability in phase 3 (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barre Syndrome (GlobeNewswire)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barr Syndrome (GlobeNewswire)
Jun-03-24 04:30PM	Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data (GlobeNewswire) -5.18%
May-20-24 09:35AM	Annexon (ANNX) Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.08%
May-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 02:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones (GlobeNewswire)
May-09-24 08:00AM	Annexon Biosciences to Present at the Bank of America Health Care Conference (GlobeNewswire)
May-07-24 12:30PM	Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting (GlobeNewswire)
May-01-24 10:15AM	Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? (Zacks)
08:00AM	Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting (GlobeNewswire)
09:35AM	Loading…
Apr-25-24 09:35AM	Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX) (Zacks)
Apr-17-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks) -10.36%
Apr-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.89%
09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-10-24 06:15PM	Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Apr-03-24 08:00AM	Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 12:00PM	What Makes Annexon (ANNX) a New Buy Stock (Zacks) -7.53%
09:55AM	Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade (Zacks)
Mar-28-24 05:31AM	Annexon Inc (ANNX) Reports Year-End Financials, Aligns with Analyst Projections (GuruFocus.com) -8.19%
Mar-26-24 08:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q4 2023 (InvestorPlace) +13.52%
04:05PM	Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones (GlobeNewswire)
Mar-18-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.98%
Mar-14-24 08:40AM	Why Annexon (ANNX) Might Surprise This Earnings Season (Zacks)
Mar-12-24 02:51PM	J.P. Morgan Predicts up to 140% Rally for These 2 Strong Buy Stocks (TipRanks)
Feb-27-24 08:00AM	Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-21-24 08:00AM	Annexon to Host Virtual R&D Day on Guillain-Barr Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach (GlobeNewswire) -5.39%
Feb-20-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-13-24 01:10PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Annexon Inc (GuruFocus.com) -7.73%
Jan-18-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.87%
Jan-17-24 11:06AM	Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How (Zacks)
Jan-07-24 08:00PM	Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases (GlobeNewswire)
Dec-27-23 06:30AM	Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 05:27PM	Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +29.51%
05:10PM	Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint (GlobeNewswire)
05:08PM	Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway (GlobeNewswire)
Dec-18-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-23 04:01PM	Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +8.37%
Nov-14-23 07:20PM	Annexon Inc (ANNX) Reports Q3 2023 Financial Results and Clinical Progress (GuruFocus.com) +9.73%
Nov-13-23 06:30AM	Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results (GlobeNewswire) +6.35%
Nov-09-23 06:30AM	Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference (GlobeNewswire)
Oct-24-23 06:30AM	Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy (GlobeNewswire) +8.33%
Oct-18-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-10-23 06:30AM	Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Sep-19-23 06:30AM	Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-18-23 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-23 09:35AM	Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX) (Zacks)
Aug-07-23 06:30AM	Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-02-23 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-30-23 12:00PM	Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy (GlobeNewswire)
Jul-27-23 06:30AM	Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer (GlobeNewswire) -6.82%
Jul-24-23 06:30AM	Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023 (GlobeNewswire)
Jun-14-23 08:36AM	Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation (Simply Wall St.) -5.48%
May-30-23 10:40AM	Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why (Zacks)
May-26-23 03:05AM	4 big analyst cuts: Snowflake downgraded twice on guidance miss (Investing.com) +35.71%
May-25-23 11:52AM	Why Shares of Annexon Are Plummeting Thursday (Motley Fool) -59.38%
10:12AM	Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study (Benzinga)
May-24-23 04:01PM	Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function (GlobeNewswire) -7.84%
May-16-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.46%
May-08-23 04:01PM	Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress (GlobeNewswire)
Apr-11-23 06:30AM	Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +5.95%
Mar-25-23 08:04AM	One Annexon, Inc. (NASDAQ:ANNX) insider upped their stake by 59% in the previous year (Simply Wall St.)
Mar-06-23 06:30AM	Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones (GlobeNewswire) -6.77%
Feb-27-23 06:30AM	Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-16-23 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-23 07:35AM	Annexon, Inc.'s (NASDAQ:ANNX) Intrinsic Value Is Potentially 27% Above Its Share Price (Simply Wall St.)
Jan-17-23 04:30PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-23 09:00AM	Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises (GlobeNewswire)
Jan-06-23 06:30AM	Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio (GlobeNewswire) +5.29%
Jan-04-23 06:30AM	Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-01-22 09:55AM	Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a Bet (Zacks)
Nov-21-22 06:13AM	We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate (Simply Wall St.)
Nov-17-22 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-15-22 09:55AM	How Much Upside is Left in Annexon, Inc. (ANNX)? Wall Street Analysts Think 246% (Zacks)
Nov-03-22 06:30AM	Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023 (GlobeNewswire)
Oct-18-22 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.75%
Oct-11-22 07:01AM	A Annexon, Inc. (NASDAQ:ANNX) insider increased their holdings by 59% last year (Simply Wall St.)
Sep-16-22 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-22 05:56PM	Amid Huntington's disease hopes and failures, Annexon targets new approach (American City Business Journals)
Aug-17-22 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Jul 15 '24	Sale	6.02	1,106	6,658	71,365	Jul 17 04:46 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Jul 15 '24	Sale	6.03	1,104	6,657	86,468	Jul 17 04:48 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Jul 15 '24	Sale	6.02	784	4,720	94,622	Jul 17 04:49 PM
Carson William H.	Director	Jul 01 '24	Buy	5.00	3,200	16,000	12,800	Jul 02 05:43 PM
Carson William H.	Director	Jun 03 '24	Buy	4.83	3,200	15,459	9,600	Jun 05 04:23 PM
Carson William H.	Director	May 01 '24	Buy	4.68	3,200	14,982	6,400	May 03 04:15 PM
Carson William H.	Director	Apr 08 '24	Buy	6.07	3,200	19,411	3,200	Apr 10 07:17 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 20 '24	Sale	5.51	2,604	14,348	72,471	Feb 21 04:31 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 20 '24	Sale	5.53	2,593	14,339	82,058	Feb 21 04:31 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 20 '24	Sale	5.48	1,951	10,691	85,641	Feb 21 04:31 PM
Love Douglas	PRESIDENT AND CEO	Feb 12 '24	Sale	5.54	5,782	32,032	196,121	Feb 14 07:56 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 12 '24	Sale	5.54	1,810	10,027	36,075	Feb 14 07:52 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 12 '24	Sale	5.54	1,809	10,022	45,651	Feb 14 07:54 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 12 '24	Sale	5.53	1,349	7,460	48,592	Feb 14 07:59 PM
Yednock Ted	EVP & Chief Innovation Officer	Dec 27 '23	Option Exercise	1.63	21,000	34,176	21,000	Dec 29 04:12 PM
Yednock Ted	EVP & Chief Innovation Officer	Dec 27 '23	Sale	4.52	21,000	94,966	0	Dec 29 04:12 PM
Satter Muneer A	Director	Dec 26 '23	Buy	2.88	350,000	1,008,000	7,406,024	Dec 28 04:30 PM

Open in Screener

XLO

Xilio Therapeutics Inc

Jul 26 • 04:00PM ET

1.01

Dollar change +0.05
Percentage change 5.33	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-2.57	Insider Own	43.84%	Shs Outstand	27.61M	Perf Week	4.12%
Market Cap	37.28M	Forward P/E	-	EPS next Y	-0.94	Insider Trans	3.08%	Shs Float	20.73M	Perf Month	10.73%
Income	-70.96M	PEG	-	EPS next Q	-0.23	Inst Own	11.21%	Short Float	0.70%	Perf Quarter	0.00%
Sales	0.00M	P/S	-	EPS this Y	49.82%	Inst Trans	-4.43%	Short Ratio	0.53	Perf Half Y	57.81%
Book/sh	0.75	P/B	1.35	EPS next Y	32.62%	ROA	-73.11%	Short Interest	0.14M	Perf Year	-64.18%
Cash/sh	0.92	P/C	1.10	EPS next 5Y	-	ROE	-128.37%	52W Range	0.49 - 2.94	Perf YTD	83.64%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-44.91%	ROI	-211.02%	52W High	-65.65%	Beta	-0.07
Dividend TTM	-	Quick Ratio	2.19	Sales past 5Y	0.00%	Gross Margin	-	52W Low	106.12%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	2.19	EPS Y/Y TTM	21.31%	Oper. Margin	0.00%	RSI (14)	53.70	Volatility	8.15% 7.22%
Employees	73	Debt/Eq	0.35	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.50	Target Price	5.50
Option/Short	No / Yes	LT Debt/Eq	0.31	EPS Q/Q	25.34%	Payout	-	Rel Volume	0.33	Prev Close	0.96
Sales Surprise	-100.00%	EPS Surprise	-463.64%	Sales Q/Q	-	Earnings	May 14 BMO	Avg Volume	273.00K	Price	1.01
SMA20	5.49%	SMA50	0.61%	SMA200	-3.16%	Trades		Volume	88,769	Change	5.33%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-21-22	Initiated	Chardan Capital Markets	Buy	$7
Jan-10-22	Initiated	H.C. Wainwright	Buy	$36
Nov-16-21	Initiated	Raymond James	Outperform	$31
Nov-16-21	Initiated	Morgan Stanley	Overweight	$32
Nov-16-21	Initiated	Guggenheim	Buy	$40
Nov-16-21	Initiated	Cowen	Outperform

Jun-13-24 04:05PM	Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors (GlobeNewswire)
May-29-24 06:05AM	Gilead and Cartography enter deal to develop cancer therapies (Pharmaceutical Technology)
May-14-24 01:54PM	XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
Apr-16-24 09:14AM	Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why (Zacks)
10:53PM	Loading…
Apr-01-24 10:53PM	XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +41.67%
04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-28-24 11:10AM	Why Is Xilio Therapeutics (XLO) Stock up 168% Today? (InvestorPlace) +69.01%
07:05AM	Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing (GlobeNewswire)
07:00AM	Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program (GlobeNewswire)
06:45AM	Gilead bets on Xilio cancer drug as biotech restructures (BioPharma Dive)
Feb-28-24 04:01PM	Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +5.60% +7.42%
Jan-31-24 04:01PM	Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:30AM	Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies (GlobeNewswire)
Dec-07-23 07:30AM	Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data (GlobeNewswire)
04:01PM	Loading…
Nov-09-23 04:01PM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire) -13.04% -10.63%
Nov-03-23 12:00PM	Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors (GlobeNewswire)
Oct-31-23 09:15AM	Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting (GlobeNewswire)
Sep-27-23 05:02PM	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-05-23 08:30AM	Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer (GlobeNewswire)
07:30AM	Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-18-23 04:27AM	Q2 2023 Xilio Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 04:05PM	Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer (GlobeNewswire)
May-25-23 05:01PM	Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors (GlobeNewswire)
May-09-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-03-23 04:05PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.09%
Mar-02-23 04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -7.37%
Feb-27-23 07:30AM	Xilio Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.72%
Feb-16-23 07:30AM	Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
07:30AM	Loading…
Feb-02-23 07:30AM	Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-26-23 05:30AM	Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most (Simply Wall St.)
Jan-25-23 09:45AM	These 2 Strong Buy Penny Stocks Are on Track for Massive Gains, Say Analysts (TipRanks) +36.92%
Nov-23-22 07:30AM	Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12 (GlobeNewswire) +7.94%
Nov-09-22 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 07:30AM	Xilio Therapeutics to Present at Cowen 6th Annual IO Next Summit (GlobeNewswire)
Sep-22-22 04:05PM	Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference (GlobeNewswire)
Sep-15-22 04:05PM	Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors (GlobeNewswire) +15.38%
Sep-06-22 04:05PM	Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +8.21%
Aug-11-22 09:41AM	Is Xilio Therapeutics (NASDAQ:XLO) In A Good Position To Invest In Growth? (Simply Wall St.)
Aug-09-22 07:30AM	Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results (GlobeNewswire) -26.22%
Jun-16-22 07:30AM	Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President (GlobeNewswire)
May-18-22 07:30AM	Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -9.56%
May-17-22 07:30AM	Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer (GlobeNewswire) -5.18%
May-12-22 07:30AM	Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results (GlobeNewswire)
Apr-07-22 06:30AM	Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-01-22 06:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) -7.56%
Feb-28-22 06:30AM	Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference (GlobeNewswire) -10.42%
Feb-07-22 05:38PM	RiverVest Venture Management LLC Buys Xilio Therapeutics Inc (GuruFocus.com)
Feb-03-22 06:30AM	Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day (GlobeNewswire)
Jan-25-22 10:27AM	Are Institutions Heavily Invested In Xilio Therapeutics, Inc.'s (NASDAQ:XLO) Shares? (Simply Wall St.)
Jan-20-22 07:30AM	Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors (GlobeNewswire) +9.79%
Jan-06-22 07:30AM	Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors (GlobeNewswire)
Dec-02-21 07:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results (GlobeNewswire) -12.46%
Nov-12-21 07:00AM	Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting (GlobeNewswire) -6.69%
Oct-27-21 07:45AM	4 Stocks Insiders Are Buying (Benzinga)
Oct-26-21 04:05PM	Xilio Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire)

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473	Apr 03 06:50 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 08 '24	Sale	0.64	733	469	2,019,563	Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 08 '24	Sale	0.64	267	171	734,546	Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 12 '24	Sale	0.83	1,540	1,278	2,020,296	Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 12 '24	Sale	0.83	560	465	734,813	Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 11 '24	Sale	0.87	1,566	1,362	2,021,836	Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 11 '24	Sale	0.87	569	495	735,373	Jan 16 06:16 PM

ANNX

Annexon Inc

XLO

Xilio Therapeutics Inc

Upgrade your FINVIZ experience